Cardiology

Results of the OPTIMIZE trial presented

A new study demonstrates that some patients may not need to receive prolonged anti-clotting therapy after drug-eluting stent (DES) implantation with the Endeavor zotarolimus-eluting stent, and that shortening the duration ...

Cardiology

Personalized antiplatelet treatment improves outcome after PCI

Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012.

Cardiology

Antiplatelet drugs don't up ICH risk in new study

(HealthDay)—Pre-existing antiplatelet use does not seem to be associated with an increased risk of ischemic hemorrhage (ICH), according to an observational study published in the February issue of Academic Emergency Medicine.

Cardiology

Global platelet reactivity and high risk ACS patients

Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012.

Cardiology

One antiplatelet drug after heart valve replacement

Current treatment guidelines say patients who undergo minimally invasive aortic heart valve replacements should receive two antiplatelet drugs to reduce the risk of dangerous blood clots.

Cardiology

Most bleeding events in non-CVD patients are GI-related

(HealthDay)—Among a cohort of individuals without cardiovascular disease (CVD) not receiving antiplatelet therapy, most major bleeding events involved gastrointestinal bleeding and 7 percent of bleeding events were fatal, ...

Cardiology

Dipyrone negates aspirin's antiplatelet effect

(HealthDay)—There is an unfavorable pharmacological drug interaction between the non-narcotic analgesic dipyrone and aspirin in patients with coronary artery disease (CAD), according to research published online Aug. 14 ...

Cardiology

Individual short-term responses to antiplatelet therapy vary

(HealthDay)—For patients with ischemic heart disease, responses to antiplatelet therapy (APT) vary between pre-discharge and one week after discharge from hospital, according to a study published online March 21 in the ...

page 4 from 5